Nivolumab plus ipilimumab has shown clinical benefit in nonrandomized studies of MSI-H or dMMR metastatic colorectal cancer. In this phase 3 open-label trial, we randomly assigned patients with ...

Previous systemic therapies received, including adjuvant treatment, are listed in the Data Supplement (Table S2). Fig 1. Patient flow. IPI, ipilimumab; NIVO, nivolumab. Median follow-up for OS was ...